Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The historical rank and industry rank for Relief Therapeutics Holding's 3-Year Dividend Growth Rate or its related term are showing as below:
XSWX:RLF's 3-Year Dividend Growth Rate is not ranked *
in the Biotechnology industry.
Industry Median: 5.1 * Ranked among companies with meaningful 3-Year Dividend Growth Rate only.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.
2. Dividend Yield % measures how much a company pays out in dividends each year relative to its share price.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Relief Therapeutics Holding 3-Year Dividend Growth Rate Related Terms>
XSWX:RLF vs KTTA, OSRH, LIMN: 3-Year Dividend Growth Rate Comparison
For the Biotechnology subindustry, Relief Therapeutics Holding's 3-Year Dividend Growth Rate, along with its competitors' market caps and 3-Year Dividend Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Relief Therapeutics Holding 3-Year Dividend Growth Rate vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Relief Therapeutics Holding's 3-Year Dividend Growth Rate distribution charts can be found below:
* The bar in red indicates where Relief Therapeutics Holding's 3-Year Dividend Growth Rate falls into.
This is the average annual rate that a company has been raising its dividends. The growth rate is calculated with expontential compound based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.
What does a 3-Year Dividend Growth Rate of 0.00% mean?
Relief Therapeutics Holding (XSWX:RLF) has a 3-Year Dividend Growth Rate of 0.00% as of Jun. 2025. 3-Year Dividend Growth Rate is the company's three-year average growth of dividend payout. View historical data on Relief Therapeutics Holding and its competitors.
Is Relief Therapeutics Holding's 3-Year Dividend Growth Rate too high?
Relief Therapeutics Holding's current 3-Year Dividend Growth Rate is 0.00%. Overall, Relief Therapeutics Holding has a GF Score™ of 20/100, reflecting its overall financial health beyond just this single metric.
How does Relief Therapeutics Holding's 3-Year Dividend Growth Rate compare to KTTA and OSRH?
Relief Therapeutics Holding's 3-Year Dividend Growth Rate of 0.00% can be compared against companies in the Biotechnology industry. The industry median 3-Year Dividend Growth Rate is 5.10. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year Dividend Growth Rate for a Biotechnology company?
The median 3-Year Dividend Growth Rate among Biotechnology companies is 5.10, based on 94 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year Dividend Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year Dividend Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year Dividend Growth Rate mean?
A high 3-Year Dividend Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year Dividend Growth Rate is the company's three-year average growth of dividend payout. View historical data on Relief Therapeutics Holding and its competitors. For the Biotechnology industry, the median 3-Year Dividend Growth Rate is 5.10 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Relief Therapeutics Holding's current 3-Year Dividend Growth Rate is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Relief Therapeutics Holding stock overvalued right now?
Relief Therapeutics Holding (XSWX:RLF) has a current 3-Year Dividend Growth Rate of 0.00%. The stock's GF Value™ is CHF6.28, compared to a current price of CHF3.00 — trading 52.2% below its estimated fair value. The current 3-Year Dividend Growth Rate is 0.00%. Relief Therapeutics Holding's overall GF Score™ is 20/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year Dividend Growth Rate calculated?
3-Year Dividend Growth Rate is calculated from a company's financial statements. For Relief Therapeutics Holding (XSWX:RLF), the current 3-Year Dividend Growth Rate is 0.00% as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Relief Therapeutics Holding (XSWX:RLF) Overvalued in 2026?
Based on GuruFocus' analysis, Relief Therapeutics Holding stock appears to be undervalued.
The current stock price of CHF3.00 is trading 52.2% below its estimated GF Value™ of CHF6.28.
Key valuation signals for XSWX:RLF:
3-Year Dividend Growth Rate: 0.00%
GF Value™: CHF6.28 vs. price of CHF3.00 (52.2% below fair value)
No single metric tells the full story. See the XSWX:RLF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Relief Therapeutics Holding SA is engaged in the research, development, and commercialization of biopharmaceutical products. It mainly develops drugs of natural human origin. It has a focus on commercial products, and the development program pipeline is focused on three main areas: rare genetic, metabolic disorders, rare connective tissue disorders, and rare lung diseases. Its pipeline includes various drug candidates in their different stages of development, such as RLF-TD011 and RLF-100, among others. It also has commercial legacy products like Cambia, Setofilm, Voltadol, and Voltfast, among others. Geographically, the company generates a majority of its revenue from Europe (excluding Switzerland) and the rest from North America, Switzerland, and the rest of the world.
20GF Score
Get the complete analysis for XSWX:RLF
3-Year Dividend Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:RLF has been successfully added to your 
